fbpx
EVENTS|NEWS|CONTACT|DONATE
Read Our Newsletter

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
nivolumab opdivo
Aug 28 2020

Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric Cancer

Gastric cancer patients taking the immune-boosting drug Opdivo in a clinical trial had a disease control rate of 39%, according to a study presented at the ESMO World Congress on Gastrointestinal Cancer.

Read Source

Social Media

   

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Please join with us to fuel the next wave of progress.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Together, we will defeat stomach cancer.

Together, we will defeat stomach cancer.

MORE INFODONATE
X